Clarient Diagnostic Services, Inc., a GE Healthcare company, and Insight Genetics, Inc., have entered a worldwide licensing agreement granting Clarient rights to develop a genetic test covering the ALK (anaplastic lymphoma kinase) biomarker, a target for several classes of cancer drugs. Clarient plans to develop and evaluate the performance characteristics of a quantitative PCR-based test that detects increased transcription of the ALK gene. Rearrangements involving the ALK gene are implicated ...